TY - JOUR
T1 - Irinotecan in combination with new agents
AU - Vanhoefer, U.
AU - Rougier, P.
AU - Borner, M.
AU - Muñoz, A.
AU - Van Laethem, J. L.
AU - Sobrero, A.
PY - 2004/6
Y1 - 2004/6
N2 - Today, irinotecan in combination with bolus and/or infusional 5-FU/FA constitutes a standard first-line treatment for patients with metastatic colorectal cancer. In an attempt to further improve clinical outcome, the use of irinotecan in combination with novel, targeted agents has been investigated. The theoretical attraction of combining irinotecan with targeted therapies is that this can improve the efficacy of treatment, but, due to the mainly non-overlapping toxicities of the agents involved, the toxicity of treatment should not be exacerbated. In this article we discuss recent data from clinical studies looking at the combinations of irinotecan with the 5-fluorouracil (5-FU) pro-drug, capecitabine, the cyclo-oxygenase (COX-2) inhibitor, celecoxib, and monoclonal antibodies against the epidermal growth factor receptor (cetuximab) and vascular endothelial growth factor (bevacizumab).
AB - Today, irinotecan in combination with bolus and/or infusional 5-FU/FA constitutes a standard first-line treatment for patients with metastatic colorectal cancer. In an attempt to further improve clinical outcome, the use of irinotecan in combination with novel, targeted agents has been investigated. The theoretical attraction of combining irinotecan with targeted therapies is that this can improve the efficacy of treatment, but, due to the mainly non-overlapping toxicities of the agents involved, the toxicity of treatment should not be exacerbated. In this article we discuss recent data from clinical studies looking at the combinations of irinotecan with the 5-fluorouracil (5-FU) pro-drug, capecitabine, the cyclo-oxygenase (COX-2) inhibitor, celecoxib, and monoclonal antibodies against the epidermal growth factor receptor (cetuximab) and vascular endothelial growth factor (bevacizumab).
KW - Bevacizumab
KW - Capecitabine
KW - Celecoxib
KW - Cetuximab
KW - Colorectal cancer
KW - Irinotecan
UR - http://www.scopus.com/inward/record.url?scp=2642565940&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2642565940&partnerID=8YFLogxK
U2 - 10.1016/j.ejcsup.2004.04.010
DO - 10.1016/j.ejcsup.2004.04.010
M3 - Article
AN - SCOPUS:2642565940
VL - 2
SP - 14
EP - 20
JO - European Journal of Cancer, Supplement
JF - European Journal of Cancer, Supplement
SN - 1359-6349
IS - 7
ER -